Entries by Max

Dual-Action Nanomaterial Eradicates Cancer Cells And Spares Healthy Tissue

/in /by

Scientists at Oregon State University have pioneered a groundbreaking nanomaterial that selectively annihilates cancer cells by harnessing the tumors’ own hostile chemical environment, while leaving healthy tissues completely unscathed. This innovative approach, detailed in a recent study published in Advanced Functional Materials, represents a major leap in chemodynamic therapy (CDT), an emerging treatment strategy that […]

Phase 1 Trial GTB-5550, a Immunotherapy Targeting B7-H3 in Solid Tumors (Including mCRPC)

/in , , /by

A new immunotherapy called GTB-5550 targeting B7-H3 on cancer cells has received FDA clearance for its first human trial (expected to start in the first half of 2026), offering fresh hope particularly for advanced prostate cancer patients exhausted by standard treatments. GTB-5550 is a TriKE molecule that binds natural killer (NK) cells from the immune […]

WOLVERINE Study Shows The Benefits of Metastases Directed Therapy

/in /by

The WOLVERINE study is a major analysis combining patient data from seven phase 2 trials, published in The Lancet Oncology. It looked at 574 men with oligometastatic prostate cancer (meaning up to five spots of cancer spread), mostly to bones or lymph nodes. Six of those trials (472 men) directly compared adding metastasis-directed therapy (MDT) […]

UPDATE: Phase 1 Trial for OP-3136 in mCRPC Started Recruiting

/in , , /by

The first-in-human phase 1 trial of OP-3136, a novel orally bioavailable KAT6A/B inhibitor for solid tumors, started recruiting, with the prostate cancer cohort focusing on men with metastatic castration-resistant prostate cancer (mCRPC). This represents a significant expansion of OP-3136 beyond its initial focus on estrogen receptor-positive breast cancer, following encouraging preclinical data presented at AACR […]

Alliance A222001 Phase 2 Trial: Oxybutynin Looks Promising for Hot Flashes in Men Under ADT

/in , , , , /by

The Alliance A222001 study, published in the Journal of Clinical Oncology in January 2026, found that oxybutynin, a drug typically used to treat overactive bladder, significantly reduces hot flashes in men receiving androgen-deprivation therapy (ADT), with improvements occurring within the first week of treatment and sustained throughout the study period. The findings could reshape how […]

Phase 1/2 JASPER Trial: Ruxolitinib Plus Enzalutamide for mCRPC

/in , , , /by

The JASPER trial is a phase 1/2 study launching from the University of Michigan, takes a fundamentally different approach to castration-resistant prostate cancer by targeting the molecular machinery driving cancer plasticity from the start: the JAK/STAT inflammatory signaling axis. Understanding why this strategy makes biological sense requires stepping into what we now know about how […]

Newsletter 5/2026

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Another week of fighting against our common enemy. And another wave of new weapons.! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. ​ […]

ANDROMEDA Trial: Alpha vs. Beta PSMA Therapy

/in , , /by

The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]

AlphaGenome: a New AI Tool to Understand DNA

/in /by

Imagine you have a long string of DNA code, a million letters long. A new AI tool called AlphaGenome reads that code and predicts exactly what it does. It tells you how active genes are, how DNA folds open or closed, where proteins stick to it, and even how far-apart parts of DNA touch each […]

Nanotech Advancement: Relief from Prostate Cancer Bone Pain on the Horizon

/in , /by

A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]